Skip to main content
Clinical Trials/NCT00578110
NCT00578110UnknownNot Applicable

SBIR II Instrument for Glaucoma Early Detection and Monitoring

Synabridge Corporation5 sites in 1 country180 target enrollmentStarted: January 1, 2008Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Enrollment
180
Locations
5
Primary Endpoint
sensitivity and specificity

Study Overview

Brief Summary

To introduce a rapid and objective electrophysiological technique that can assess visual function in the magnocellular pathway, which is thought to be affected in early-stage glaucoma.

Detailed Description

The clinical study will evaluate a novel instrument designed to record visual evoked potentials elicited by stimuli determined in prior research (Greenstein et al., 1998; Badr et al., 2003) to drive select visual pathways that exhibit glaucomatous damage in an efficient and automated manner. The results obtained with this novel device will be compared with results obtained using an existing commercial device. Statistical results, sensitivity and specificity, will be generated for the assessment of the accuracy of the test to discriminate glaucoma patients from controls. Repeatability of the test will also be analyzed based on the test-retest results.

Visual evoked potential (VEP) is a measure of neural function in the eye and brain. Three skin electrodes are placed on the surface of the scalp to record the electrical activity from the brain while the subject is observing a flickering stimulus with isolated-check/dot pattern. The whole procedure is non-invasive and the risks are negligible.

Isolated-Check/dot Stimuli of about 10 Hz with luminance contrast of 10%, 15%, -10%, and -15% will be used to test each eye. Eight samples for each stimulus will be recorded. Each experimental run takes 2 seconds. The T-circ statistical method is performed to process the data, and the VEP signal to noise ratio (SNR) is calculated in order to obtain an optimized condition (stimulus and threshold) to separate glaucoma patients and normal group.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Parallel
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Ages
40 Years to 75 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Age: 40 - 75 years old
  • •Visual acuity: 20/30 or better

Exclusion Criteria

  • •Eye disease other than glaucoma

Arms & Interventions

Group 1

Experimental

Glaucoma Patients

Intervention: Glaucoma Diagnosis, Name: Neucodia (Device)

Group 2

Experimental

Glaucoma suspects

Intervention: Glaucoma Diagnosis, Name: Neucodia (Device)

Group 3

Active Comparator

Controls

Intervention: Glaucoma Diagnosis, Name: Neucodia (Device)

Outcomes

Primary Outcomes

sensitivity and specificity

Time Frame: one year

Secondary Outcomes

  • repeatability(one year)

Investigators

Sponsor Class
Industry

Study Sites (5)

Loading locations...

Similar Trials

Instrument for Glaucoma Early Detection... | Clinical Trial